CN103619820B - 可用作溴区结构域抑制剂的四氢喹啉衍生物 - Google Patents

可用作溴区结构域抑制剂的四氢喹啉衍生物 Download PDF

Info

Publication number
CN103619820B
CN103619820B CN201280029939.XA CN201280029939A CN103619820B CN 103619820 B CN103619820 B CN 103619820B CN 201280029939 A CN201280029939 A CN 201280029939A CN 103619820 B CN103619820 B CN 103619820B
Authority
CN
China
Prior art keywords
compound
methyl
amino
mmol
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280029939.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN103619820A (zh
Inventor
D.阿曼
E.H.德蒙
D.J.米歇尔
R.J.沃森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of CN103619820A publication Critical patent/CN103619820A/zh
Application granted granted Critical
Publication of CN103619820B publication Critical patent/CN103619820B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201280029939.XA 2011-04-21 2012-04-19 可用作溴区结构域抑制剂的四氢喹啉衍生物 Expired - Fee Related CN103619820B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1106743.6 2011-04-21
GB201106743A GB201106743D0 (en) 2011-04-21 2011-04-21 Novel compounds
PCT/EP2012/057111 WO2012143413A1 (en) 2011-04-21 2012-04-19 Tetrahydroquinoline derivatives useful as bromodomain inhibitors

Publications (2)

Publication Number Publication Date
CN103619820A CN103619820A (zh) 2014-03-05
CN103619820B true CN103619820B (zh) 2015-08-19

Family

ID=44147335

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280029939.XA Expired - Fee Related CN103619820B (zh) 2011-04-21 2012-04-19 可用作溴区结构域抑制剂的四氢喹啉衍生物

Country Status (16)

Country Link
US (1) US9029395B2 (cg-RX-API-DMAC7.html)
EP (1) EP2699550B1 (cg-RX-API-DMAC7.html)
JP (1) JP5840763B2 (cg-RX-API-DMAC7.html)
KR (1) KR101896599B1 (cg-RX-API-DMAC7.html)
CN (1) CN103619820B (cg-RX-API-DMAC7.html)
AU (1) AU2012244759B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013026834A2 (cg-RX-API-DMAC7.html)
CA (1) CA2832763C (cg-RX-API-DMAC7.html)
EA (1) EA022341B1 (cg-RX-API-DMAC7.html)
ES (1) ES2544302T3 (cg-RX-API-DMAC7.html)
GB (1) GB201106743D0 (cg-RX-API-DMAC7.html)
IL (1) IL228707A (cg-RX-API-DMAC7.html)
MX (1) MX338515B (cg-RX-API-DMAC7.html)
SG (1) SG194469A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012143413A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201307645B (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201107325D0 (en) 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. ブロモドメイン阻害剤としての新規複素環式化合物
CN105189461B (zh) * 2013-03-14 2018-05-15 葛兰素史克知识产权第二有限公司 2,3-二取代的1-酰基-4-氨基-1,2,3,4-四氢喹啉衍生物和它们作为溴结构域抑制剂的用途
EA035469B1 (ru) 2013-03-15 2020-06-22 Инсайт Холдингс Корпорейшн Трициклические гетероциклы как ингибиторы белков бэт
KR102307566B1 (ko) 2013-06-21 2021-10-05 제니쓰 에피제네틱스 리미티드 신규한 바이사이클릭 브로모도메인 억제제
CN105473581B (zh) 2013-06-21 2019-04-23 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新取代的双环化合物
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
CA2919948C (en) 2013-07-31 2020-07-21 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
WO2015120393A1 (en) 2014-02-10 2015-08-13 Concert Pharmaceuticals, Inc. Substituted triazolobenzodiazepines
SMT202000133T1 (it) 2014-04-23 2020-05-08 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet
SG10201900631TA (en) 2014-08-01 2019-02-27 Nuevolution As Compounds active towards bromodomains
WO2016038120A1 (en) 2014-09-12 2016-03-17 Glaxosmithkline Intellectual Property (No.2) Limited Tetrahydroquinoline derivatives as bromodomain inhibitors
JP6599979B2 (ja) 2014-09-15 2019-10-30 インサイト・コーポレイション Betタンパク質阻害剤として用いるための三環式複素環化合物
KR20170055549A (ko) * 2014-10-02 2017-05-19 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 화합물
HK1245246A1 (zh) 2014-12-01 2018-08-24 恒翼生物医药科技(上海)有限公司 作为溴域抑制剂的取代吡啶酮
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
WO2016092375A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
CN107406438B (zh) 2014-12-17 2021-05-14 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CN109715625B (zh) 2016-06-20 2022-04-19 因赛特公司 Bet抑制剂的结晶固体形式
EP3490552B1 (en) 2016-07-26 2022-11-23 University of Southern California Selective bromodomain inhibition of fungal bdf1
US11028051B2 (en) * 2016-12-13 2021-06-08 St. Jude Children's Research Hospital Tetrahydroquinoline-based bromodomain inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011054851A1 (en) * 2009-11-05 2011-05-12 Glaxosmithkline Llc Novel process
WO2011054848A1 (en) * 2009-11-05 2011-05-12 Glaxosmithkline Llc Thetrahydroquinolines derivatives as bromodomain inhibitors
WO2011054841A1 (en) * 2009-11-05 2011-05-12 Glaxosmithkline Llc Tetrahydroquinoline derivatives and their pharmaceutical use
WO2011054843A1 (en) * 2009-11-05 2011-05-12 Glaxosmithkline Llc Bromodomain inhibitors for treating autoimmune and inflammatory diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
BRPI0416128B8 (pt) 2003-11-03 2021-06-22 Glaxo Group Ltd dispositivo de dispensação de fluido
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Brd2ブロモドメイン結合剤
CN101910182B (zh) 2007-12-28 2013-07-17 田边三菱制药株式会社 抗癌剂
WO2010113498A1 (ja) * 2009-03-31 2010-10-07 興和株式会社 テトラヒドロキノリン化合物を有効成分とする貧血の予防及び/又は治療剤
GB201106750D0 (en) * 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201107325D0 (en) * 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
WO2013033268A2 (en) * 2011-08-29 2013-03-07 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011054851A1 (en) * 2009-11-05 2011-05-12 Glaxosmithkline Llc Novel process
WO2011054848A1 (en) * 2009-11-05 2011-05-12 Glaxosmithkline Llc Thetrahydroquinolines derivatives as bromodomain inhibitors
WO2011054841A1 (en) * 2009-11-05 2011-05-12 Glaxosmithkline Llc Tetrahydroquinoline derivatives and their pharmaceutical use
WO2011054843A1 (en) * 2009-11-05 2011-05-12 Glaxosmithkline Llc Bromodomain inhibitors for treating autoimmune and inflammatory diseases

Also Published As

Publication number Publication date
JP5840763B2 (ja) 2016-01-06
WO2012143413A1 (en) 2012-10-26
IL228707A (en) 2016-09-29
US9029395B2 (en) 2015-05-12
US20140039006A1 (en) 2014-02-06
AU2012244759B2 (en) 2016-03-03
KR20140025484A (ko) 2014-03-04
CA2832763C (en) 2019-09-24
JP2014511891A (ja) 2014-05-19
ZA201307645B (en) 2015-04-29
IL228707A0 (en) 2013-12-31
MX338515B (es) 2016-04-20
ES2544302T3 (es) 2015-08-28
EA022341B1 (ru) 2015-12-30
KR101896599B1 (ko) 2018-09-07
AU2012244759A1 (en) 2013-10-31
EP2699550B1 (en) 2015-06-10
EA201391285A1 (ru) 2014-04-30
EP2699550A1 (en) 2014-02-26
MX2013012190A (es) 2014-01-31
BR112013026834A2 (pt) 2016-12-27
CN103619820A (zh) 2014-03-05
GB201106743D0 (en) 2011-06-01
SG194469A1 (en) 2013-12-30
CA2832763A1 (en) 2012-10-26

Similar Documents

Publication Publication Date Title
CN103619820A (zh) 可用作溴区结构域抑制剂的四氢喹啉衍生物
JP5905075B2 (ja) ブロモドメイン阻害剤として有用なテトラヒドロキノリン誘導体
CN103889984B (zh) 4-(8-甲氧基-1-(1-甲氧基丙烷-2-基)-2-(四氢-2H-吡喃-4-基)-1H-咪唑并[4,5-c]喹啉-7-基)-3,5-二甲基异噁唑及其作为溴结构域抑制剂的用途
JP5926793B2 (ja) ブロモドメイン阻害剤としてのテトラヒドロキノリン誘導体
JP5856673B2 (ja) 7−(3,5−ジメチル−4−イソオキサゾリル)−8−(メチルオキシ)−1H−イミダゾ[4,5−c]キノリン誘導体
CN102762569B (zh) 苯并二氮杂*溴区结构域抑制剂
JP5819840B2 (ja) ブロモドメイン阻害剤としてのテトラヒドロキノリン誘導体
CN110621661A (zh) 作为溴结构域抑制剂的吡啶基衍生物
HK1229802A (en) 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150819

Termination date: 20210419